INDEGENE LIMITED Intrinsic Value
INDGN · Healthcare · Current price ₹510.9
Is INDEGENE LIMITED undervalued?
DocStoX estimates the fair value of INDEGENE LIMITED at ₹404 per share, versus the current market price of ₹511. That puts the stock about -20.9% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹147), Relative P/E (₹1,020), Graham floor (₹221). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹147 (bear) to ₹404 (base) to ₹1,020 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹511 versus an intrinsic value of ₹404, INDEGENE LIMITED currently offers -20.9% of negative margin (i.e. a premium).
More on INDEGENE LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.